2Burns T,Patrick D.Social function as an outcome measure in schizophrenia studies.Acta Psychiatr Scand,2007,116(6):403-418.
3Nicholl D,Nasrallah H,Nuamah I,et al.Personal and social functioning in schizophrenia:defining a clinically meaningful measure of maintenance in relapse prevention.Curr Med Res Opin,2010,26(6):1471-1484.
4Mannaert E,Vermeulen A,Remmerie B,et al.Pharmacokinetic profile of long-acting injectable risperidone at steady-state:comparison with oral administration.Encephale,2005,31(5):609-615.
5Sümegi A.Neurobiological and pharmacologic aspects of atypical antipsychotic drugs.Orv Hetil,2009,150(33):1539-1544.
6Millan MJ,Buccafusco JJ,Loiseau F.The dopamine D(3)receptor antagonist,S33138,counters cognitive impairment in a range of rodent and primate procedures.Int J Neuropsychopharmacol,2010,13(8):1035-1051.
7Loiseau F,Millan MJ.Blockade of dopamine D(3)receptors in frontal cortex,but not in sub-cortical structures,enhances social recognition in rats:similar actions of D(1)receptor agonists,but not of D(2)antagonists.Eur Neuropsychopharmacal,2009,19(1):23-33.
8Gefvert O,Eriksson B,Persson P,et al.Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone(Risperdal Consta)in patients with schizophrenia.Int J Neuropsychopharmacol,2005,8(1):27-36.
9Morosini PL,Magliano L,Brambilla L,et al.Development,reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale(SOFAS)to assess routine social functioning.Acta Psychiatr Scand,2000,101(4):323-329.
10Bai YM,Chen TT,Wu B,et al.A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients:12-week randomized,single-blind study.Pharmacopsychiatry,2006,39(4):135-141.
